A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)

Conditions: Wet Macular Degeneration, Neovascular Age-related Macular Degeneration, Macular Degeneration

Sex: All

Ages: 50 Years – 85 Years

Phase: PHASE2

Enrollment: 90

Sponsor: Sylentis, S.A.

Location: Czechia

Summary

The goal of this clinical trial is to compare the safety and effect on visual acuity of three different doses of SYL1801 eye drops.

Eligibility Criteria

Inclusion Criteria:Signed informed consentActive subfoveal or juxtafoveal choroidal neovascularization secondary to AMDBest Corrected Visual Acuity (BCVA) between 70-25 letters (ETDRS) at ScreeningIntraretinal or subretinal fluidCentral Subfield Thickness > 300 µmExclusion Criteria:Pregnant or breastfeeding females or those with a positive pregnancy test.Females of childbearing potential who will not use a medically acceptable contraceptive methodCurrent, previous chronic or recurrent condition according to the investigator's judgement.Concomitant treatment or prior ocular procedure or surgery, or alteration of the dose of systemic medicationsConcurrent disease in the study eyePrevious treatment with systemic anti-Vascular Endothelial Growing Factor (Anti-VEGF) drugs or pro-VEGF treatmentsConcurrent disease in the study eye, other than AMD

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05637255). StuddyBuddy aggregates publicly available trial information.